BlackBerry Limited (BB)

BlackBerry's stock closed at $9.22 on November 9, 2026, up 5.49% on the session and 14.96% over the past week, and it now trades above its 20-day, 50-day and 200-day averages. The move comes after a run that has carried the shares 102.19% higher over the past year, while the stock still sits 32.16% below its 52-week high of $13.59. Investors are weighing that momentum against a valuation that already prices in a premium to peers, with a trailing P/E of 70.92 against a sector median of 35.1.

The stock rose 14.96% over the past week and 5.49% in the latest session, and it has moved from a 52-week low of $3.12 to $9.22. The 50-day SMA of $8.49 sits 31.61% above the 200-day SMA of $7.01 by a wide margin, meaning the 50-day average is 21.14% above the 200-day average. The price is 8.64% above its 50-day SMA and 31.61% above its 200-day SMA. The RSI of 55.1 is in the neutral zone, and the MACD line is positive, so the momentum signal supports the trend without signalling overheating.

BlackBerry has beaten the EPS estimate in each of the last five reports, covering September 25, 2025 through September 24, 2026. The September 24, 2026 report delivered adjusted EPS of $0.07 against an estimate of $0.04, a 75.00% beat, yet the share price fell 5.96% in the first session after that report. Earlier reports lifted the stock: the June 25, 2026 report was followed by a 10.25% rise. Analysts expect revenue to grow 14.0% this fiscal year.

At $9.22 the stock trades at a trailing P/E of 70.92, 16.0% above the sector median of 35.1, and a price-to-sales ratio of 8.82, 16.1% above the sector median of 7.6. Reported GAAP EPS over the last twelve months is $0.13, which is far below the adjusted quarterly figures. The net profit margin of 13.09% and operating margin of 22.66% are solid, but return on equity of 10.60% is below the sector median of 13.4%. Debt-to-equity of 0.28 keeps the balance sheet conservative.

Of eight analysts with a current rating, two rate the stock Buy or Strong Buy, four rate it Hold, and two rate it Sell or Strong Sell, so the consensus is Hold. Amerx started coverage at Buy on October 8, 2026, while Canaccord Genuity kept its Hold rating on September 25, 2026 and RBC Capital kept its Sector Perform rating on September 21 and September 25, 2026. Over the last 18 months insiders sold $9.7M of stock across 40 sales and made no open-market purchases. Such sales are often planned in advance or made to cover tax on vesting shares, so they carry less weight than purchases would.

The base case is that the stock keeps its upward trend while earnings growth continues to support it. Analysts expect fiscal-year EPS of $0.21, up 28.6%, and next fiscal year EPS of $0.24, up 14.6%, which gives the trend a fundamental anchor. The analyst median target of $9.50 sits only 3.0% above the price, and the highest target of $13.00 is the bull case. The main risks are the stock's premium multiple and the fact that its last earnings beat was followed by a 5.96% drop in the first session. A sustained move toward $13.59 would need revenue and earnings to keep beating expectations; a loss of the 20-day EMA with weaker results would shift the picture toward the lower analyst targets, starting at $6.60.

Support sits first at the 20-day EMA of $8.74, followed by the 50-day SMA at $8.49, which the price has held above since the stock's recent advance. Below that, the 200-day SMA at $7.01 is the next level investors watch as a longer-term trend line. The 52-week low of $3.12 is the deepest reference point. Resistance is the 52-week high of $13.59, the level a further rise would have to meet first.